News
Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...
Pembrolizumab alone or in combination with chemotherapy can provide long-term benefits over chemotherapy alone in recurrent or metastatic HNSCC, data suggest.
New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...
Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient (dMMR) early-stage solid cancers who ...
MSD has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in the US state of Delaware.
12h
Medpage Today on MSNRA Doesn't Diminish Checkpoint Inhibitors' Survival BenefitIt had been hoped that RA patients might actually benefit more from these drugs, known as immune checkpoint inhibitors (ICIs) ...
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USDup by 5%[1] at a ...
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, today announced compelling results from a new study demonstrating the ability of the Cellworks Platform ...
Merck breaks ground on new $1 billion biologics center of excellence in Wilmington, Delaware: Rahway, New Jersey Wednesday, April 30, 2025, 09:00 Hrs [IST] Merck, known as MSD out ...
LUND, SE / ACCESS Newswire / April 29, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...
Pfizer is deeply undervalued, and has a high dividend yield, and I see tons of institutions and analysts buying the dip. Read ...
Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results